Gentamicin
An aminoglycoside antibiotic used to treat serious bacterial infections caused by gram-negative organisms, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It works by binding to bacterial ribosomes and inhibiting protein synthesis, leading to bacterial cell death. Due to risks of kidney damage and hearing loss, blood levels and kidney function require careful monitoring during treatment.
分子量
477.6000 g/mol
LogP
-4.10
TPSA
200.00 Ų
リピンスキーの五則
不適合
治療領域
作用機序
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
2D構造
Cite this structure
Embed this structure
SMILES
CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
InChI
InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3
Molecular Formula
C21H43N5O7
HBD / HBA
8 / 12
回転可能結合数
7
重原子数
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
An aminoglycoside antibiotic used to treat serious bacterial infections caused by gram-negative organisms, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It works by binding to bacterial ribosomes and inhibiting protein synthesis, leading to bacterial cell death. Due to risks of kidney damage and hearing loss, blood levels and kidney function require careful monitoring during treatment.
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Yes, Gentamicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067485. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3467. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gentamicin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gentamicin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gentamicin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gentamicin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gentamicin"></drugfyi-drug>